Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development, and diagnostics has announced MSIntuit® CRC v21, a next-generation AI solution. Aimed at transforming the detection and treatment of colorectal cancer (CRC), MSIntuit® CRC v2 will initially launch as an RUO version in the US on Roche’s navify® Digital Pathology enterprise software. MSIntuit® CRC v2 builds upon the success of the CE-IVD-certified MSIntuit® CRC, integrating cutting-edge machine learning models developed by Owkin with...